Abstract 338P
Background
Mucositis is one of the most common oral complications arising in cancer patients receiving chemotherapy and/or radiotherapy. The pain and distress of mucositis can be enough to cause disability during the course of treatment. Vitamin E has been found to have antioxidant and free radical scavenging properties which can reduce inflammation. To date, vitamin E supplementation in the form of tablets or pastes have been tried with different levels of success in several trials, however, there is no clear recommendation for its use. This study was done to obtain a more precise estimate of the efficacy of vitamin E on radiotherapy and chemotherapy-induced mucositis, in the hopes of providing an easily available, inexpensive but effective treatment for this condition.
Methods
A systematic search of Pubmed, Embase, Cochrane, Clinical trials databases and hand search were utilized to identify randomized controlled trials (RCTs) dated until December 2019, investigating the efficacy of oral or topical vitamin E in reducing oral mucositis in cancer patients receiving chemotherapy or radiotherapy. Using the random effects model, pooled Odds Ratio (OR) with 95% confidence intervals (CI) were calculated in measuring the incidence of improvement or resolution of oral mucositis.
Results
Four RCTs were included (N=171). The pooled rate of mucositis resolution was significantly higher in the group treated with Vitamin E (84.7% vs 51.2%), with an odds ratio of 6.04 (95% CI 2.46-14.84, p < 0.0001). Heterogeneity between the studies was minimal (I2 0-20%). Vitamin E was well-tolerated and there were no severe adverse effects reported in the studies.
Conclusions
The results showed that vitamin E (topical or oral) was significantly associated with higher rates of improvement of oral mucositis among solid cancer patients who underwent chemotherapy or radiotherapy. Our results suggest that vitamin E can be considered a simple, non-toxic, yet effective therapy for oral mucositis. Subgroup analysis based on type and dose of vitamin E administration, type of anti-tumor treatment, and type of cancer can be done once with additional studies in the future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Textbook outcome as a measure of surgical quality assessment and prognosis in gastric neuroendocrine carcinoma: A large multicenter sample analysis
Presenter: You-Xin Gao
Session: e-Poster Display Session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session